Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT.

Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.

3.

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.

Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.

Cancer. 2003 Jan 1;97(1):1-11.

4.

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.

Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.

5.

Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?

Reynolds C, Davidson JA, Lindor NM, Glazebrook KN, Jakub JW, Degnim AC, Sandhu NP, Walsh MF, Hartmann LC, Boughey JC.

Ann Surg Oncol. 2011 Oct;18(11):3102-9. doi: 10.1245/s10434-011-1908-8. Epub 2011 Sep 27.

PMID:
21947588
6.

HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.

van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.

PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.

7.

Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.

Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, Hudis CA, Offit K, Robson ME.

Cancer. 2003 Apr 1;97(7):1601-8.

8.

BRCA-associated breast cancer: absence of a characteristic immunophenotype.

Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K.

Cancer Res. 1998 May 1;58(9):1839-42.

9.

Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer.

Mangia A, Tommasi S, Bruno M, Malfettone A, D'Amico C, Zito FA, Paradiso A, Simone G.

Oncol Rep. 2010 Jun;23(6):1641-5.

PMID:
20428820
10.

[BRCA1- and BRCA2- associated breast carcinomas].

Ahrens P, Kreipe HH.

Pathologe. 2009 Dec;30 Suppl 2:207-9. doi: 10.1007/s00292-009-1223-3. German.

PMID:
19795125
11.

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.

Neoplasma. 2010;57(4):325-32.

PMID:
20429623
12.

Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.

Buerger H, Simon R, Schäfer KL, Diallo R, Littmann R, Poremba C, van Diest PJ, Dockhorn-Dworniczak B, Böcker W.

Mol Pathol. 2000 Jun;53(3):118-21.

13.

Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.

de Juan Jiménez I, Esteban Cardeñosa E, Palanca Suela S, Barragán González E, Aznar Carretero I, Munárriz Gandía B, Santaballa Bertran A, Torregrosa Maicas MD, Guillén Ponce C, Sánchez Heras AB, Bayón Lara A, Fuster Lluch O, Bolufer Gilabert P.

Fam Cancer. 2012 Mar;11(1):49-56. doi: 10.1007/s10689-011-9481-7.

PMID:
21918853
14.

PML protein expression in hereditary and sporadic breast cancer.

Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z.

Neoplasma. 2007;54(4):263-8.

PMID:
17822314
15.

Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.

Hall MJ, Reid JE, Wenstrup RJ.

Cancer Prev Res (Phila). 2010 Dec;3(12):1579-85. doi: 10.1158/1940-6207.CAPR-09-0218.

16.

ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.

Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC, Jenkins RB.

Genes Chromosomes Cancer. 2004 Sep;41(1):1-11.

PMID:
15236312
17.

The BARD1 Cys557Ser variant and breast cancer risk in Iceland.

Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.

PLoS Med. 2006 Jul;3(7):e217.

18.

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.

Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.

PMID:
26026974
19.

Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction.

Naidu R, Wahab NA, Yadav M, Kutty MK, Nair S.

Int J Mol Med. 2001 Aug;8(2):193-8.

PMID:
11445874
20.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683

Supplemental Content

Support Center